Many early-phase studies towards an HIV cure or controlled remission involve substantial risks for study participants, but a host of ethical solutions are conceivable. […]
Month: April 2017
Nick Hopkinson: What is breathing worth? The economic cost of lung disease
It is no secret that the UK healthcare system is under strain. The percentage of GDP spent on healthcare is projected to fall to 6.6% by 2020/21, back to the same […]
Jennifer Dixon: The NHS Five Year Forward View—the task now is delivery
As the good book notes “Without a vision the people perish.” While not on a biblical scale, the Five Year Forward View published in 2014 set out what was a broad […]
Chris Moulton: The answer to the NHS’s never ending A+E problem is actually fairly simple
Everybody wants world peace; everybody wants an end to poverty. And we all want the NHS to have a safe, efficient and cost-effective emergency service. The trouble is that nobody […]
Richard Lehman’s journal review—3 April 2017
NEJM 30 Mar 2017 Vol 376 Rivaroxaban vs aspirin long after VTE The longer you give anticoagulants to people following venous thromboembolism, the fewer subsequent thromboembolic events they will have. […]
Martin McKee: Article 50 has been triggered. Now what?
The sound of ideology slamming into a wall of reality is already echoing throughout Whitehall, says Martin McKee, as he unpicks some of the consequences of Brexit. […]